Cough medicine could help doctors identify how breast cancer patients metabolize... (er enzyme: CYP3A. Furthermore a patient'...)

Cough medicine could help doctors identify how breast cancer patients metabolize tamoxifen

Date:11/18/2010

er enzyme: CYP3A. Furthermore, a patient's metabolism is not only influenced by genes, but also by other factors such as co-medication and environmental factors. The dextromethorphan phenotyping test takes all these factors into account in predicting tamoxifen metabolism," said Mrs de Graan.

The test needs to be refined and improved so that fewer blood samples are required and it is easier to use; it also needs to be tested in another group of patients. If this proves to be successful, then the researchers will have to develop a dosing strategy and test it in a phase III trial in order to compare it with current practice.

"Research today focuses more on the treatment of the individual patient. We now know that every patient responds differently to therapy. It is largely unknown why one patient experiences more or fewer side effects or why some patients respond better or worse to therapy. Therefore, it is highly important to identify prognostic factors that predict this response. We believe that tailored therapy will optimise treatment with systemic therapy. The current dosing strategy does not take individual differences into account like co-medication, DNA difference, life-style factors like smoking behaviour, and alcohol consumption. Genotyping tamoxifen-treated patients is just one step towards individual treatment, but different results are reported in the literature. We investigated another way of predicting tamoxifen metabolism by phenotyping, which takes various individual differences into account. Future research will tell which strategy for individualising treatment will be the best to implement in daily practice. Our dextromethorphan test could aid in future studies on the association of tamoxifen and CYP2D6 genotype and phenotype, and ultimately in the personalisation of tamoxifen treatment," concluded Mrs de Graan.

'/>"/>

Contact: Emma Mason
wordmason@mac.om
ECCO-the European CanCer Organisation
Source:Eurekalert

1

GOOD

Page: 1 2 3
Related medicine news :

1. Too Few Adults Vaccinated Against Whooping Cough: CDC
2. Spread of Whooping Cough Raises Concern
3. Commentary suggests alternatives to routine use of OTC cold/cough meds in children
4. New commentary suggests alternatives to routine use of OTC cold/cough meds in children
5. TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference
6. Lung cancer patients are the centerpiece for Northwestern medicine quality of care study
7. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
8. The color of medicine
9. Texas Center for Cancer Nanomedicine targets 2 tough cancers
10. Organic solvent system may improve catalyst recycling and create new nanomedicine uses
11. Neuroimaging leader to receive the 2010 Taylor Prize in Medicine

Post Your Comments:

(Date:5/23/2013)... May 23, 2013 The vast majority ... deal of control over their level of physical activity, ... far fewer are actually taking that control. Those ... Council (IFIC) Foundation’s 2013 Food & Health Survey. , ... it’s possible to have “a great deal of control” ...

(Date:5/23/2013)... New York (PRWEB) May 23, 2013 ... protecting the rights of victims injured by defective medical ... Litigation Counsel Matthew J. McCauley has been appointed Co-Lead ... Re: Mirena IUD Products Liability Litigation (Case 7:13-md-02434-CS). The ... Co-Lead and Liaison Counsel are to submit their proposal ...

(Date:5/23/2013)... 23 (HealthDay News) -- Symptoms of borderline personality ... complicating diagnosis and treatment. But researchers in Canada ... be unique to borderline personality disorder: a tendency ... , "They have difficulty processing facial emotions and ... face," said Anthony Ruocco, a clinical neuropsychologist and ...

(Date:5/23/2013)... isolated from a person who died from H7N9 avian ... and be transmitted between ferrets. Ferrets are often used ... transmission of influenza virus between ferrets can provide clues ... in people. The research was supported, in part, by ... of the National Institutes of Health. , The researchers ...

(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Six ... a million dollars by Lyme Research Alliance, the nation's ... major academic institutions. The studies focus on the epidemiology of, ... diseases. , “LRA is proud to support the ... and the brightest men and women in the field ...

Breaking Medicine News(10 mins):Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2 Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3 Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4 Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2 Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2 Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3 Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2 Health News:Six Investigators Awarded Lyme Research Alliance Grants 2 Health News:Six Investigators Awarded Lyme Research Alliance Grants 3 Health News:Six Investigators Awarded Lyme Research Alliance Grants 4

[0] Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus”[0] U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation [0] People With Borderline Personality Disorder May Misinterpret Facial Emotions [0] Ferrets, pigs susceptible to H7N9 avian influenza virus [0] Six Investigators Awarded Lyme Research Alliance Grants

... Scientific understanding and medical treatments for autism spectrum disorders ... but much remains to be done, say experts from ... of Philadelphia who published a scientific review of the ... by autism researchers throughout the world, and give our ...

... , BALTIMORE, Oct. 14 Lynn R. Chincheck, DDS, and ... breast cancer on Sunday, Oct. 18, as part of Baltimore,s ... participate by patients who have battled breast cancer, Team Chincheck ... , "After meeting several patients who have been affected by ...

... Advice Networks , the nation,s leading provider of physician ... track consumer purchase behavior, not just purchase intent, for ... their revenue and justify investments designed to capture market ... their health messages to purchase volume. To address this ...

... Almost a billion people across the planet do not have ... a mere $5 can give one person clean water for ... to doing good and supporting good in communities through a ... bringing clean and safe drinking water to people in developing ...

... Cardium Therapeutics (NYSE Amex: CXM ) today ... product candidate Excellagen(TM), a collagen-based topical gel for use ... in patients with chronic or non-chronic diabetic foot ulcers. ... study findings reported today from the Excellarate(TM) Phase 2b ...

... ... it will feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at ... October 17-21. , ... Ann Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of ...

Cached Medicine News:Health News:Experts summarize state of the science in autism disorders 2 Health News:Team Chincheck Goes Miles for Smiles 2 Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2 Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3 Health News:Tom's of Maine and charity: water Team Up to Fund Global Clean Water Projects With Instant, Mobile Donation Campaign 2 Health News:Tom's of Maine and charity: water Team Up to Fund Global Clean Water Projects With Instant, Mobile Donation Campaign 3 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 2 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 3 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 4 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 5 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 6 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 7 Health News:Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers 8 Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2 Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3

Experts summarize state of the science in autism disorders Team Chincheck Goes Miles for Smiles Healthy Advice Networks Now Able to Track Consumer Purchase Behavior Tom's of Maine and charity: water Team Up to Fund Global Clean Water Projects With Instant, Mobile Donation Campaign Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery

(Date:5/23/2013)... , May 23, 2013 MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...

(Date:5/23/2013)... 23, 2013 The need to add tissue ... was highlighted prominently at the 108 th ... in San Diego. According to SonaCare Medical, a ... (HIFU) technology, the need for image-guided technologies to ... to consider minimally invasive ablative treatments, was addressed ...

(Date:5/23/2013)... 23, 2013 Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...

Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5 Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6 Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2 Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3

[0] MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 [0] Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting [0] Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients

... 17, 2007 - ProNAi Therapeutics,Inc., a biopharmaceutical ... based on DNA interference (DNAi), today,announced that ... demonstrated preclinical in vivo efficacy in,xenograft mice ... including curative,events for difficult-to-treat Burkitt's Lymphoma., Dr. ...

... April 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced ... 2 clinical trial of the triplet combination ... in the,first-line treatment of advanced non-small cell ... clinically significant,improvement in both progression-free survival and ...

Cached Medicine Technology:ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma 2 Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2 Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3 Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4

ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

... The Macula Plus® 5.5 ... observation of the optic ... Use it with your ... detecting choroidal neovascular membranes, ...

... iQ200 Automated Urine Microscopy Analyzer (iQ200) ... (APR) software to classify urine particles ... results. The iQ200 eliminates most technologist ... particle images by automating specimen preparation, ...

... is based on the C6 peptide antigen, a ... VlsE. This peptide has been shown to ... all of the antigenic reactivity of the whole ... C6 peptide is a sensitive and specific marker ...

First to USA-market, this revolutionary technology combines CBC and CRP analysis for stat results of 17 parameters within 4.5 minutes!...

Medicine Products:

Macula Plus® 5.5 iQ200 Automated Urine Microscopy Analyzer C6 B. burgdorferi (Lyme) ELISA Kit ABX Micros CRP200